Trehalose ( DrugBank: Trehalose )

3 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	3
6	Parkinson disease	1
113	Muscular dystrophy	1

2. Amyotrophic lateral sclerosis

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05597436 (ClinicalTrials.gov)	November 19, 2022	24/10/2022	Intermediate-Sized Expanded Access Study	An Expanded Access Protocol of Intravenous Trehalose Injection 90.5 mg/mL Treatment of Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Trehalose	Seelos Therapeutics, Inc.	Massachusetts General Hospital;National Institute of Neurological Disorders and Stroke (NINDS);Office of the Director, National Institutes of Health (OD)	Temporarily not available	18 Years	N/A	All			United States
2	NCT05136885 (ClinicalTrials.gov)	February 21, 2022	14/11/2021	HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose	HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose	Amyotrophic Lateral Sclerosis	Drug: SLS-005;Drug: Matching Placebo	Merit E. Cudkowicz, MD	Seelos Therapeutics, Inc.	Enrolling by invitation	18 Years	N/A	All	160	Phase 2/Phase 3	United States
3	NCT04297683 (ClinicalTrials.gov)	July 14, 2020	3/3/2020	HEALEY ALS Platform Trial - Master Protocol	HEALEY ALS Platform Trial	Amyotrophic Lateral Sclerosis	Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose	Merit E. Cudkowicz, MD	Massachusetts General Hospital	Recruiting	18 Years	N/A	All	800	Phase 2/Phase 3	United States

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05355064 (ClinicalTrials.gov)	May 2022	18/12/2021	Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease	Efficacy of Oral Administration of Trehalose in Patients With Parkinson Disease in Both Idiopathic and Induced by LRRK2 Mutation	Parkinson Disease	Drug: Trehalose	Neuromed IRCCS	NULL	Not yet recruiting	18 Years	80 Years	All	20	Phase 4	NULL

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04226924 (ClinicalTrials.gov)	June 15, 2017	15/7/2019	Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose	A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Trial of Trehalose for the Treatment of	Oculopharyngeal Muscular Dystrophy	Drug: Trehalose	Bioblast Pharma Ltd.	NULL	Withdrawn	50 Years	70 Years	All	0	Phase 2	Canada